(Q52896102)

English

Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.

scientific article published on 22 April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors. (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Steffen Weikert

1

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

Carsten Kempkensteffen

2

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

Jonas Busch

3

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

Manfred Johannsen

4

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

Viktor Grünwald

5

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

Kaja Zimmermann

6

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

Anne Flörcken

7

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

Jörg Westermann

8

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

Lisa Weinkauf

9

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

Kurt Miller

10

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

Ulrich Keilholz

11

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

publication date

22 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

World Journal of Urology

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

31

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

4

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

805-809

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

https://scigraph.springernature.com/pub.10.1007/s00345-011-0676-1

0 references

Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Update on systemic therapies of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Update on the medical treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Temsirolimus in VEGF-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Sequential therapy with sorafenib and sunitinib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Sequential sorafenib and sunitinib for renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00345-011-0676-1

21 January 2018

Identifiers

10.1007/S00345-011-0676-1

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/21512806

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52896102&oldid=1531343479"